{"pmcid": 5971365, "prompt_strategy": "zeroshot", "model": "gpt-5.1", "extractions": [{"outcome": "clinically meaningful improvement at week 144 (⩾3-point increase on the SDMT)", "intervention": "daclizumab beta", "comparator": "intramuscular (IM) interferon (IFN) beta-1a", "intervention_group_size": 287, "comparator_group_size": 277, "intervention_events": 188, "comparator_events": 144, "pmcid": "24(6)795-804", "outcome_type": "binary"}, {"outcome": "Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients", "intervention": "daclizumab beta", "comparator": "intramuscular (IM) interferon (IFN) beta-1a", "intervention_group_size": 287, "comparator_group_size": 277, "intervention_mean": 6.3, "comparator_mean": 3.1, "intervention_standard_deviation": 12.6, "comparator_standard_deviation": 13.2, "pmcid": "24(6)795-804", "outcome_type": "continuous"}, {"outcome": "Symbol Digit Modalities Test (SDMT) score at week 96", "intervention": "daclizumab beta", "comparator": "intramuscular (IM) interferon (IFN) beta-1a", "intervention_group_size": 720, "comparator_group_size": 682, "intervention_mean": 4.1, "comparator_mean": 2.9, "intervention_standard_deviation": 12.4, "comparator_standard_deviation": 12.7, "pmcid": "24(6)795-804", "outcome_type": "continuous"}, {"outcome": "clinically meaningful worsening at week 96 (⩾3-point decrease on the SDMT)", "intervention": "daclizumab beta", "comparator": "intramuscular (IM) interferon (IFN) beta-1a", "intervention_group_size": 720, "comparator_group_size": 682, "intervention_events": 140, "comparator_events": 169, "pmcid": "24(6)795-804", "outcome_type": "binary"}, {"outcome": "clinically meaningful improvement at week 96 (⩾3-point increase on the SDMT)", "intervention": "daclizumab beta", "comparator": "intramuscular (IM) interferon (IFN) beta-1a", "intervention_group_size": 720, "comparator_group_size": 682, "intervention_events": 432, "comparator_events": 369, "pmcid": "24(6)795-804", "outcome_type": "binary"}], "errors": []}
